Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

CHMP Recommends EU Approval of Obe-Cel for Relapsed/Refractory B-ALL

May 23rd 2025

The EMA’s CHMP has recommended the approval of obecabtagene autoleucel for adult patients with relapsed/refractory B-ALL.

Updated STARGLO Data Show Maintained OS Benefit With Glofitamab Plus Chemo in R/R DLBCL

May 23rd 2025

Two-year follow-up data continued to show an overall survival benefit with glofitamab plus chemotherapy in relapsed/refractory DLBCL.

Artificial Intelligence Proves Its Worth in Cancer Treatment, Drug Development, and Other Real-World Applications

May 22nd 2025

Multiple experts on artificial intelligence in cancer care discuss its ever-expanding role in several areas of oncology.

Treatment Trends and Ongoing Research in Pediatric Acute Leukemia

May 22nd 2025

Lia Gore, MD, and Sarah K. Tasian, MD, discuss ongoing research in pediatric acute leukemia.

Factors to Consider in Pediatric Acute Leukemia Management

May 22nd 2025

Lia Gore, MD, and Sarah K. Tasian, MD, discuss key factors for the management of pediatric acute leukemia.

Breaking Down Treatment Expectations With Revumenib in Pediatric KMT2A+ R/R Acute Leukemia

May 22nd 2025

Lia Gore, MD, and Sarah K. Tasian, MD, discuss treatment expectations with revumenib in pediatric relapsed/refractory acute leukemia.

Integrating 25-mg Tablets of Revumenib Into Pediatric R/R Acute Leukemia Management

May 22nd 2025

Lia Gore, MD, and Sarah K. Tasian, MD, discuss the use of 25-mg tablets of revumenib in pediatric KMT2A-translocated relapsed/refractory acute leukemia.

When to Test for KMT2A Rearrangements and Other Alterations in Pediatric Acute Leukemia

May 22nd 2025

Lia Gore, MD, and Sarah K. Tasian, MD, discuss the optimal timing of testing for KMT2A rearrangements in pediatric acute leukemia.

Implications of the FDA Approval of Revumenib in KMT2A+ R/R Acute Leukemia

May 22nd 2025

Lia Gore, MD, and Sarah K. Tasian, MD, on the significance of the FDA approval of revumenib in KMT2A-rearranged relapsed/refractory acute leukemia.

Current Treatment Strategies in Pediatric R/R AML and ALL

May 21st 2025

Lia Gore, MD, and Sarah K. Tasian, MD, discuss current treatment trends in pediatric relapsed/refractory acute leukemia.

Pola-R-CHP Is Associated With Improved 2-Year PFS Rates in Older Untreated DLBCL Population

May 21st 2025

Pola-R-CHP demonstrated clinically meaningful PFS and safety in older patients with previously untreated diffuse large B-cell lymphoma.

China’s NMPA Approves Tafasitamab Plus Lenalidomide in Transplant-Ineligible R/R DLBCL

May 21st 2025

Tafasitamab plus lenalidomide has received NMPA approval for patients with relapsed/refractory DLBCL who are ineligible for ASCT.

Dr Falchi on the Safety of Fixed-Duration Epcoritamab Plus Lenalidomide/Rituximab in R/R Follicular Lymphoma

May 20th 2025

Lorenzo Falchi, MD, discusses the safety and pharmacodynamics of fixed-duration epcoritamab plus lenalidomide and rituximab in relapsed/refractory follicular lymphoma

Lymphodepletion Enhances MAR T-Cell Expansion and Persistence in R/R Lymphoma

May 20th 2025

Lymphodepletion was associated with enhanced MAR T-cell response and antitumor activity with MT-601 in patients with relapsed/refractory lymphoma.

FDA ODAC Votes Against the Applicability of STARGLO Data for Glofitamab Plus Chemo for U.S. Patients With R/R DLBCL

May 20th 2025

The FDA’s ODAC voted against the applicability of STARGLO trial results to U.S. patients with relapsed/refractory DLBCL.

Hematology Experts Outline the Top Abstracts to Watch at the 2025 ASCO Annual Meeting

May 19th 2025

Oncology experts detail their most highly-anticipated hematology abstracts and data to watch at the upcoming 2025 ASCO Annual Meeting.

Dr Oluwole on the Importance of Assessing the Onset and Incidence of Axi-Cel–Related Neurotoxicity in R/R DLBCL

May 16th 2025

Olalekan O. Oluwole, MD, MPH, discusses how AE assessment could guide post-infusion monitoring periods and outpatient axi-cel administration in LBCL.

Dr Patel on the Safety Profile of Bispecific Antibodies in Follicular Lymphoma

May 14th 2025

Vivek G. Patel, MD, discusses the safety profile of bispecific antibodies for the treatment of patients with follicular lymphoma.

Dr Falchi on the Efficacy of Fixed-Duration Epcoritamab Plus Lenalidomide and Rituximab in R/R Follicular Lymphoma

May 14th 2025

Lorenzo Falchi, MD, discusses the safety and efficacy of fixed-duration epcoritamab plus lenalidomide and rituximab in relapsed/refractory follicular lymphoma.

AlloNK Plus Rituximab Induces Durable Responses in R/R B-Cell NHL

May 14th 2025

Longer-term phase 1/2 data with AB-101 plus rituximab showed high, durable responses in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.